We are live on
!
Find out more
VPC
Vestal Point Capital Portfolio holdings
AUM
$3.58B
1-Year Est. Return
189.12%
This Fund
S&P 500
This Quarter
Est. Return
+67.45%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$315M
(+17%)
Cap. Flow
-$130M
Cap. Flow
% of AUM
-5.88%
Top 10 Holdings %
Top 10 Hldgs %
38.34%
Holding
95
New
23
Increased
27
Reduced
21
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$74.6M |
| 2 |
ABVX
Abivax
ABVX
|
+$61.3M |
| 3 |
Becton Dickinson
BDX
|
+$55.7M |
| 4 |
DexCom
DXCM
|
+$51.4M |
| 5 |
Repligen
RGEN
|
+$48.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACLX
Arcellx
ACLX
|
+$108M |
| 2 |
Cytokinetics
CYTK
|
+$92.7M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$84M |
| 4 |
uniQure
QURE
|
+$63.1M |
| 5 |
KALV
KalVista Pharmaceuticals
KALV
|
+$54.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Sutro Biopharma
STRO
$421M
| $2.26M | 0.1% |
260,000
| – | – |
|
|
OKUR
77
OnKure Therapeutics
OKUR
$168M
| $1.75M | 0.08% |
635,000
| – | – |
|
78
Pulmonx
LUNG
$87.6M
| $1.34M | 0.06% |
+830,000
| New | +$1.74M |
|
79
MacroGenics
MGNX
$257M
| $470K | 0.02% |
280,000
| – | – |
|
80
Tenax Therapeutics
TENX
$503M
| $407K | 0.02% |
53,439
| – | – |
|
81
Traws Pharma
TRAW
$8.1M
| $278K | 0.01% |
150,000
+200
| +0.1% | +$326 |
|
82
Atara Biotherapeutics
ATRA
$76.1M
| – | – |
-94,085
| Closed | -$726K |
|
83
Cogent Biosciences
COGT
$7.24B
| – | – |
-3,080,000
| Closed | -$22.1M |
|
84
Cooper Companies
COO
$14.5B
| – | – |
-350,000
| Closed | -$24.9M |
|
85
Edwards Lifesciences
EW
$51.7B
| – | – |
-300,000
| Closed | -$23.5M |
|
86
GE HealthCare
GEHC
$32.4B
| – | – |
-700,000
| Closed | -$51.8M |
|
87
Structure Therapeutics
GPCR
$3.78B
| – | – |
-1,200,000
| Closed | -$24.9M |
|
88
Medtronic
MDT
$112B
| – | – |
-195,000
| Closed | -$17M |
|
89
MoonLake Immunotherapeutics
MLTX
$1.55B
| – | – |
-550,000
| Closed | -$26M |
|
90
Neurocrine Biosciences
NBIX
$16.6B
| – | – |
-30,000
| Closed | -$3.77M |
|
91
Perrigo
PRGO
$1.78B
| – | – |
-625,000
| Closed | -$16.7M |
|
92
Thermo Fisher Scientific
TMO
$220B
| – | – |
-25,000
| Closed | -$10.1M |
|
93
Travere Therapeutics
TVTX
$5.78B
| – | – |
-355,000
| Closed | -$5.25M |
|
94
Viridian Therapeutics
VRDN
$2.67B
| – | – |
-100,000
| Closed | -$1.4M |
|
95
Zimmer Biomet
ZBH
$18.4B
| – | – |
-50,000
| Closed | -$4.56M |
|
Similar funds
WWA
BPS
SL
AAP
SCM
ACM
TYCC
GCM
Vestal Point Capital's Q3 2025 Portfolio in Review
As of Q3 2025, Vestal Point Capital held 95 positions worth $2.21B, up 17% from $1.9B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Vestal Point Capital withdrew a net $130M in Q3 2025, closing 14 positions and reducing 21 holdings. Its most notable exit was GE HealthCare, an estimated $51.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.
Against the trend, Vestal Point Capital opened a new position in Abivax worth $84.9M.
- Vestal Point Capital's largest Q3 2025 buy was Abivax: 1,000,000 shares worth $84.9M.
- Vestal Point Capital added most to Ascendis Pharma A/S in Q3 2025, an estimated $74.6M increase.
- Vestal Point Capital's biggest Q3 2025 reduction was Arcellx, cutting an estimated $108M.
- Vestal Point Capital fully exited GE HealthCare in Q3 2025, selling an estimated $51.8M.
- Vestal Point Capital's ten largest holdings make up 38% of its $2.21B portfolio in Q3 2025.
- Vestal Point Capital opened 23 new positions and closed 14 in Q3 2025.
- Vestal Point Capital's portfolio value rose 17% quarter-over-quarter to $2.21B.
Based on Vestal Point Capital's 13F filing for Q3 2025, filed 14 Nov 2025.